Company: TVRD
Filing Date: 2025-01-27
Form Type: S-4/A
Source: 0001104659-25-006050
Chunk: 584

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-01-27
Form: S-4/A
Chunk 584
---
      ​ | ​ 
 ​ 
 ​ 
 ​ 
 ​ | ​      
 ​      
 Change 
 Amount 
 ​      
 ​      |      ​ 
      ​ 
      ​ 
      ​ | ​ 
 ​ 
 ​ 
 ​ |       ​ 
       ​ 
 Percent 
       ​ 
       ​ | ​ 
 ​ 
 ​ 
 ​ 
 ​ 
 ​ |
|:-----------------------------------------------------|:--|:------------------|-------:|:--|:-----|-------:|:--|:-------|-------:|:--|--------:|:--|
| HCC                                                  |   | $                 |  4,996 |   | $    |  1,239 |   | $      |  3,757 |   |   303.2 | % |
| IPF                                                  | ​ | ​                 |  2,991 | ​ | ​    |  2,828 | ​ | ​      |    163 | ​ |     5.8 | % |
| mBC                                                  | ​ | ​                 |  2,771 | ​ | ​    |    456 | ​ | ​      |  2,315 | ​ |   507.7 | % |
| Pre-clinical, CMC, and other (unallocated)           |   | ​                 |    715 |   | ​    |  3,340 |   | ​      | -2,625 |   |   -78.6 | % |
| TTI-109                                              |   | ​                 |    697 |   | ​    |    870 |   | ​      |   -173 |   |   -19.9 | % |
| Unallocated research and development expense:        |   | ​                 |        |   | ​    |        |   | ​      |        |   |         | ​ |
| Personnel costs (including stock-based compensation) |   | ​                 |  2,273 |   | ​    |  2,199 |   | ​      |     74 |   |     3.4 | % |
| Consultant fees and other costs                      |   | ​                 |    604 |   | ​    |    952 |   | ​      |   -348 |   |   -36.6 | % |
| Total research and development expenses              | ​ | $                 | 15,047 | ​ | $    |